Skip to main
PTHS

PTHS Stock Forecast & Price Target

PTHS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pelthos Therapeutics is expected to experience growth in the near future due to the commercialization of their recently FDA-approved product, Zelsuvmi, for the treatment of molluscum contagiosum. The company's potential for expansion is further supported by their acquisition of the rights to Xepi for the pediatric market and their pipeline of non-opioid pain treatments. However, the success of these endeavors is dependent on their clinical trials, manufacturing readiness, and regulatory interactions.

Bears say

Pelthos Therapeutics is facing potential challenges with the launch and commercialization of their novel treatment, Zelsuvmi, due to competition and reliance on physician and patient acceptance. While the company has strong leadership and a promising pipeline, potential risks in manufacturing and execution could impact financial margins. The company is currently seeking funding for commercialization and global expansion, but the success of Zelsuvmi is ultimately tied to market adoption and changing factors such as physician behavior.

PTHS has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pelthos Therapeutics Inc (PTHS) Forecast

Analysts have given PTHS a Buy based on their latest research and market trends.

According to 6 analysts, PTHS has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pelthos Therapeutics Inc (PTHS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.